News

The collaboration will allow to develop and distribute the university’s potential recombinant adenovirus vaccine for the prevention of COVID-19 infection from SARS-CoV-2. The potential vaccine, dubbed ChAdOx1 nCoV-19,

Until now, only 20% of women with ovarian cancer, those with a BRCA mutation (BRCAm), were eligible to be treated with a PARP inhibitor as monotherapy in the

The collaboration commits joint investment to accelerate rapid scale-up of segregated manufacturing capacity over the coming months to support dedicated production of Johnson & Johnson’s investigational vaccine candidate.

The open-label and phase 3 SIMPLE trial has assessed five-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalised patients with severe manifestations of COVID-19 disease.

We believe our product DEXTENZA for AC has potential as a hands-free therapy administered in the office setting as a bioresorbable, intracanalicular insert, designed to release the corticosteroid

The approval is for the use of the KEYTRUDA dosage in both monotherapy and combination therapy. According to Merck, the FDA granted the accelerated approval of the new

The partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in

The CAN-COVID study will assess the efficacy of using canakinumab for the treatment of a type of severe immune overreaction known as cytokine release syndrome (CRS) in people

Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response